Company Overview More
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children’s Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
CEO: Ingram, Douglas S.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

SRPT Sarepta Therapeutics

78.540+1.260+1.63%
Trading Session 10/28 12:35 ET
High
79.190
Open
77.530
Turnover
31.70M
Low
76.970
Prev.Close
77.280
Volume
404.34K
Market Cap
6.83B
P/E(TTM)
Loss
52Wk High
181.830
Shares
86.94M
P/E
Loss
52Wk Low
65.300
H Mkt Cap
6.53B
Bid-Ask Ratio
33.33%
Historical High
181.830
H Shares
83.15M
Vol. Ratio
1.12
Historical Low
2.598
Dividend TTM
--
Div Yield TTM
700
P/B
14.08
Dividend LFY
--
Div Yield LFY
891.26%
Turnover Ratio
0.49%
Amplitude
2.87%
Avg Price
78.404
Min Trading Unit
1
Float Market Cap
6.53B
Bid-Ask Ratio
33.33%
Historical High
181.830
Float
83.15M
Vol. Ratio
1.12
Historical Low
2.598
Dividend TTM
--
P/B
14.08
Dividend LFY
--
Turnover Ratio
0.49%
Amplitude
2.87%
Avg Price
78.404
Min Trading Unit
1
Price Forecast

Loading...

News